REHOVOT, Israel and BRIDGEWATER, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, Chief Executive Officer, will provide a corporate overview and business update at the Jefferies 2015 Global Healthcare Conference.
| Presentation Details: | |
| Title: | Jefferies 2015 Global Healthcare Conference |
| Date: | Thursday, June 4 |
| Time: | 9:00am Eastern Time |
| Location: | Grand Hyatt Hotel, New York City |
| Webcast: | http://wsw.com/webcast/jeff88/fomx |
About Foamix Pharmaceuticals
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
CONTACT: Dorit Hayon, BD manager Foamix Pharmaceuticals Ltd. +972-8-9316233 ir@foamixpharma.com U.S. Investor Relations Andrew McDonald LifeSci Advisors, LLC 646-597-6987 andrew@lifesciadvisors.com
Help employers find you! Check out all the jobs and post your resume.
